#EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes – Endpoints News

#EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes  Endpoints NewsEli Lilly obesity drug data adds pressure on Novo Nordisk  Yahoo! Finance CanadaWhy Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s  CNBCOzempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial  ScienceAlertBlockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs  Scientific American